PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AUTL vs. ATRA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AUTL and ATRA is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

AUTL vs. ATRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Autolus Therapeutics plc (AUTL) and Atara Biotherapeutics, Inc. (ATRA). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%100.00%SeptemberOctoberNovemberDecember2025February
-45.40%
10.96%
AUTL
ATRA

Key characteristics

Sharpe Ratio

AUTL:

-1.04

ATRA:

-0.49

Sortino Ratio

AUTL:

-1.92

ATRA:

-0.20

Omega Ratio

AUTL:

0.79

ATRA:

0.98

Calmar Ratio

AUTL:

-0.72

ATRA:

-0.58

Martin Ratio

AUTL:

-1.46

ATRA:

-1.25

Ulcer Index

AUTL:

47.56%

ATRA:

46.35%

Daily Std Dev

AUTL:

65.72%

ATRA:

117.63%

Max Drawdown

AUTL:

-96.58%

ATRA:

-99.64%

Current Drawdown

AUTL:

-95.92%

ATRA:

-99.46%

Fundamentals

Market Cap

AUTL:

$508.29M

ATRA:

$48.50M

EPS

AUTL:

-$1.22

ATRA:

-$25.32

Total Revenue (TTM)

AUTL:

$10.09M

ATRA:

$96.19M

Gross Profit (TTM)

AUTL:

$6.17M

ATRA:

$81.97M

EBITDA (TTM)

AUTL:

-$147.22M

ATRA:

-$65.15M

Returns By Period

In the year-to-date period, AUTL achieves a -16.60% return, which is significantly higher than ATRA's -35.39% return.


AUTL

YTD

-16.60%

1M

-14.78%

6M

-45.40%

1Y

-71.39%

5Y*

-29.50%

10Y*

N/A

ATRA

YTD

-35.39%

1M

-46.88%

6M

11.40%

1Y

-55.33%

5Y*

-52.66%

10Y*

-32.75%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AUTL vs. ATRA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AUTL
The Risk-Adjusted Performance Rank of AUTL is 55
Overall Rank
The Sharpe Ratio Rank of AUTL is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of AUTL is 22
Sortino Ratio Rank
The Omega Ratio Rank of AUTL is 55
Omega Ratio Rank
The Calmar Ratio Rank of AUTL is 77
Calmar Ratio Rank
The Martin Ratio Rank of AUTL is 66
Martin Ratio Rank

ATRA
The Risk-Adjusted Performance Rank of ATRA is 2020
Overall Rank
The Sharpe Ratio Rank of ATRA is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of ATRA is 2727
Sortino Ratio Rank
The Omega Ratio Rank of ATRA is 2727
Omega Ratio Rank
The Calmar Ratio Rank of ATRA is 1313
Calmar Ratio Rank
The Martin Ratio Rank of ATRA is 1313
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AUTL vs. ATRA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Autolus Therapeutics plc (AUTL) and Atara Biotherapeutics, Inc. (ATRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for AUTL, currently valued at -1.04, compared to the broader market-2.000.002.004.00-1.04-0.49
The chart of Sortino ratio for AUTL, currently valued at -1.92, compared to the broader market-6.00-4.00-2.000.002.004.00-1.92-0.20
The chart of Omega ratio for AUTL, currently valued at 0.79, compared to the broader market0.501.001.502.000.790.98
The chart of Calmar ratio for AUTL, currently valued at -0.72, compared to the broader market0.002.004.006.00-0.72-0.58
The chart of Martin ratio for AUTL, currently valued at -1.46, compared to the broader market0.0010.0020.0030.00-1.46-1.25
AUTL
ATRA

The current AUTL Sharpe Ratio is -1.04, which is lower than the ATRA Sharpe Ratio of -0.49. The chart below compares the historical Sharpe Ratios of AUTL and ATRA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00SeptemberOctoberNovemberDecember2025February
-1.04
-0.49
AUTL
ATRA

Dividends

AUTL vs. ATRA - Dividend Comparison

Neither AUTL nor ATRA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AUTL vs. ATRA - Drawdown Comparison

The maximum AUTL drawdown since its inception was -96.58%, roughly equal to the maximum ATRA drawdown of -99.64%. Use the drawdown chart below to compare losses from any high point for AUTL and ATRA. For additional features, visit the drawdowns tool.


-100.00%-98.00%-96.00%-94.00%-92.00%-90.00%SeptemberOctoberNovemberDecember2025February
-95.92%
-99.21%
AUTL
ATRA

Volatility

AUTL vs. ATRA - Volatility Comparison

The current volatility for Autolus Therapeutics plc (AUTL) is 15.69%, while Atara Biotherapeutics, Inc. (ATRA) has a volatility of 71.62%. This indicates that AUTL experiences smaller price fluctuations and is considered to be less risky than ATRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%30.00%40.00%50.00%60.00%70.00%SeptemberOctoberNovemberDecember2025February
15.69%
71.62%
AUTL
ATRA

Financials

AUTL vs. ATRA - Financials Comparison

This section allows you to compare key financial metrics between Autolus Therapeutics plc and Atara Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab